InvestmentHealthTech

Sٲ-ܱéFertility has raised £800,000ٴlauncha pioneering at-home fertility treatment.

Founded by embryologist David O’Rourke andFemTechspecialist TessCosad, theFemTech, based in London, aims to make fertility treatments more affordable.

The round was led by Calm/Storm VC and joined by Q Ventures.Itincludes an innovation grant from the recentInnovateUKSMART competition.

Currently, the next step for those who are unable to conceive naturally is to receive either Intrauterine Insemination (IUI) or In Vitro Fertilisation (IVF) treatments at a fertility clinic; interventions which can take a physical and emotional toll on those involvedandalso present a financial burden.

Whilst some people are eligible for initial IVF treatments through the NHS, this provision is patchy and contingent on meeting a range of criteria. Those who don’t qualify or who need tocontinue ontheir conception journey after that point must cover the costs themselves.

One cycle of IVF can cost upwards of £5,000 and one IUI treatment can cost upwards of £1,500.

The Béa product (1)

Theéproduct, set to launch later this year,will enable couples to carry outIntraCervicalInseminationat home.é’sICI method involves placing a small cup of semen close to the cervix, where it’s left in-situ for 4-12 hours. During that time, women can go about their days normally.

Following over 90 design iterations led by some of the UK’s leading embryologists, theéteam believesitsmethod will improve the chances of conception by 40% if used overthreemonths, and by as much as 60% if used oversixmonths.

It says the ICI method has been scientifically proven to have similar efficacy rates to IUI treatments.

éFertility will operate on a monthly subscription basis, providing users with two ICI devices, ovulation tests, pregnancy tests and access to an app to help track ovulation dates and the progress of their fertility journey.

The subscription will cost around £300 per month, meaning 5 months of theéICI treatment will be the same price of one round of IUI at a fertility clinic.

/high-profile-cto-joins-blood-sensing-start-up-zedsen/

“Our mission atéis to democratise access to effective fertility treatments; providing people with more options,” saidCosad.

ICI is clinically proven to be highly effective when it comes to increasing the chances of conception, but it’s not made available to people at the beginning of their fertility journey. Instead, theyhave totake a big leap into the expensive world of invasive treatments.

But for people where there’s nomedically-identifiedissue causing infertility, ICI can be the ideal way of maximising their chances of getting pregnant. We’re designing a product that enables people to do this easily and affordably, all from home.

“Infertility is sadly still a taboo and something we don’t talk enough about, meaning people often struggle through it alone. There’s something so empowering about taking your fertility journey into your own hands, andthis is whyI’m so passionate about launchingéFertility.

Throughé, we’re breaking down barriers,driving inclusion, improving access, and fundamentally cracking open the fertility market.